tezosentan has been researched along with Disease Exacerbation in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bourge, RC; Cleland, JG; Cotter, G; Davison, BA; Jondeau, G; Kobrin, I; Krum, H; McMurray, JJ; Metra, M; Milo, O; O'Connor, CM; Parker, JD; Rainisio, M; Senger, S; Teerlink, JR; Torre-Amione, G; van Veldhuisen, DJ | 1 |
| Duchman, SM; Kalra, D; Thohan, V; Torre-Amione, G | 1 |
1 review(s) available for tezosentan and Disease Exacerbation
| Article | Year |
|---|---|
Endothelin-1: a new target of therapeutic intervention for the treatment of heart failure.
Topics: Animals; Disease Models, Animal; Disease Progression; Dogs; Drug Evaluation, Preclinical; Endothelin-1; Heart Failure; Hemodynamics; Humans; Oxygen Consumption; Prognosis; Pyridines; Rabbits; Rats; Survival Analysis; Tetrazoles | 2000 |
1 trial(s) available for tezosentan and Disease Exacerbation
| Article | Year |
|---|---|
Worsening heart failure, a critical event during hospital admission for acute heart failure: results from the VERITAS study.
Topics: Acute Disease; Aged; Disease Progression; Double-Blind Method; Female; Heart Failure; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Outcome Assessment, Health Care; Patient Admission; Pyridines; Tetrazoles; Vasodilator Agents | 2014 |